Phase 2 N=50 Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
Type 2 Diabetes
Primary: Insulin Secretion — 5; 29 % increase of Ins30
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=38 Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Diabetic Foot Infections
Primary: Clinical Success (in ITT Population) — 95.7 percentage of participants
Phase 2 N=17 Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Primary: Response Rate [Stringent CR (sCR)+Complete Response (CR)+Very Good PR (VGPR)+Partial Response (PR)]Based on International Myeloma Working Group (IMWG) Criteria — 0…
Phase 2 N=12 Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
Kidney Failure
Primary: Net Iron Delivery From SFP Via the Dialysate — 692 microgram
Phase 2 N=92 A Study of DER 45-EV Gel to Treat Rosacea
Rosacea
Primary: Investigator Global Assessment (IGA) Improvement From Baseline — 37.5; 20.0; 53.3 percentage of subjects
Phase 2 N=62 Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction
Anxiety Disorder · Breast Cancer · Cognition Disorders
Primary: Retention — 71.0; 80.7 percentage of participants
Phase 2 N=90 Compression Device Versus 4-layer Compression System
Leg Ulcers
Primary: Safety Measured by the Number of Subjects With Adverse Events (Including Any Deterioration of Ulcer) — 33; 47 Number of Subjects with Adverse Events
Phase 2 N=35 A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
HCV Infection
Primary: Persistence of Resistance-Associated Variants and Phenotypic Resistance — 4; 0; 2; 0 participants
Phase 2 N=12 Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects
Chronic Hepatitis C Infection
Primary: Maximum Plasma Concentration (Cmax) of ABT-267 Following Monotherapy on Day 1 — 1.66; 41.0 ng/mL
Phase 2 N=12 A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Multiple Myeloma · Non-hodgkin's Lymphoma · Hodgkin's Disease
Primary: Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg — 7; 5 participants
Phase 2 N=30 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Chronic Hepatitis C Virus Infection
Primary: Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Monotherapy Treatment — -1.01; -0.78; -0.68; -0.26 log10 IU/mL…
Phase 2 N=21 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Squamous Cell Carcinoma of the Nasopharynx
Primary: Proportion of Patients Alive and Progression-free — 9; 12 participants
Phase 2 N=74 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
Hepatitis C · HCV · Chronic Hepatitis C Infection
Primary: Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment — -4.07; -3.91; -4.11…
Phase 2 N=11 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
Hepatitis C · HCV · Chronic Hepatitis C Infection
Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12 — 100…
Phase 2 N=50 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Chronic Hepatitis C Infection · Hepatitis C · Hepatitis C Virus
Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12 — 89.5…